Sofosbuvir is popular in the pharmaceutical headlines as of late, with more positive news for the patient population with Hepatitis C. An NIH (National Institute of Allergy and Infectious Diseases) study released exciting data which showed the use of Sofosbuvir and Ledipasvir elicited a cure rate in only six weeks’ time for patients with the Hepatitis C virus. This phenomenal time frame was unexpected by study investigators, but certainly welcomed by patients and practitioners. The study involved adult patients with Hepatitis C infections. Taking place at the National Institutes of Health, the aforementioned patients received a combination of three direct-acting drug therapies. This oral course of treatment was offered for approximately six and twelve weeks and the results were presented in the latest issue of The Lancet. The first trial saw 20 trial participants who received Sofosbuvir alongside both Ledipasvir and an experimental drug coined GS-9669. None of the clinical trial patients had previously undergone treatment of any kind for the Hepatitis C virus. Remarkably 19 of these patients who received these three therapies had a complete recovery at the 12 week mark. A second group of 20 patients were given a combination treatment of Sofosbuvir, Ledipasvir and a different experimental drug, coined GS-9451 for 6 weeks’ time. Again, this patient group had not been previously treated for the Hepatitis C virus. At the conclusion of the six week therapy a startling 19 of these patients exhibited zero signs of the Hepatitis C virus. Finally, a third group of 20 patients were administered Sofosbuvir and Ledipasvir only. This group also showed an astounding cure rate, with all 20 participants demonstrating no signs of the disease at the 12 week mark. The six week trial group’s success proved that a shorter time period for treatment was as efficacious in this instance as compared to a 12 week course of treatment.
In addition to patient cure rates being incredibly good, there were no reports of patients experiencing adverse effects from any of these Hepatitis C drug therapy combinations. The advent of these novel therapies, to be dispensed in shorter periods of time makes treatment for this virulent disease easier and efficacious for a wide swath of patients. The need for immediate treatment is urgent for patients suffering from the Hepatitis C virus, as roughly 85 percent of untreated or improperly treated cases end up leading to chronic Hepatitis C. The development of this chronic and long-term liver infection is devastating for patients.
LGM Pharma can assist clients as a supplier/distributor of the APIs Ledipasvir, CAS # 1256388-51-8 and Sofosbuvir, CAS # 1190307-88-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.